処方皮膚科治療薬の世界市場

処方皮膚科治療薬の世界市場は2030年までに808億米ドルに達する見込み

2024年に504億米ドルと推定される処方皮膚科治療薬の世界市場は、分析期間2024-2030年にCAGR 8.2%で成長し、2030年には808億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである「にきび・酒さ治療薬」は、CAGR 10.4%を記録し、分析期間終了時には223億米ドルに達すると予測されます。乾癬治療薬セグメントの成長率は、分析期間中CAGR 9.4%と推定されます。

米国市場は137億米ドルと推定、中国はCAGR13.1%で成長予測

米国の処方皮膚科治療薬市場は2024年に137億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに177億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.0%と7.9%と予測されています。欧州では、ドイツがCAGR 5.5%で成長すると予測されています。

世界の処方皮膚科治療薬市場- 主要動向と促進要因のまとめ

処方ベースの皮膚科治療へのシフトを促進するものは何か？

処方皮膚科治療薬は、医療介入を必要とする中等度から重度の皮膚状態に対処するためにデザインされた治療法のカテゴリーとして成長しています。市販のスキンケア製品とは異なり、これらの治療薬は乾癬、アトピー性皮膚炎、酒さ、尋常性ざ瘡、膿疱性汗腺炎、皮膚がんなどの慢性、炎症性、感染性、自己免疫性の皮膚疾患の治療に用いられます。皮膚の健康に対する意識の高まり、皮膚科医療へのアクセスの向上、疾患有病率の上昇に伴い、市場は過去10年間で大幅に拡大した。

持続性あるいは難治性の疾患患者には、先進的な外用薬、経口レチノイド、生物学的製剤、全身性免疫調節薬が処方されることが多くなっています。美容皮膚科と治療皮膚科の境界線も曖昧になりつつあり、色素沈着症、脱毛、光障害に対する臨床的に有効な解決策を求める患者が増加しています。社会の態度が積極的な皮膚管理へと変化するにつれ、かつては「美容上の厄介者」と見なされていた症状でさえも、医療の傘下に置かれるようになってきています。

皮膚科医、一般内科医、アレルギー専門医を含むヘルスケアプロバイダーも、疾患に対する認識が高まり、診断ツールが改善される中で、専門製品を処方する傾向が強まっています。保険適用の拡大、皮膚科を訪れる患者の増加、デジタル処方プラットフォームなどの要因が、処方箋の充填率を高め、アドヒアランスを向上させています。

どのような科学的進歩と分子革新が治療選択肢を再構築しているのか？

処方皮膚科市場では、治療の有効性と安全性プロファイルを向上させる新しい有効医薬品成分（API）、標的生物製剤、送達システムの急増が見られます。コルチコステロイド、レチノイド、抗生物質といった従来の薬剤は、現在、より優れた疾患コントロールとより少ない副作用を提供する新規の免疫調節剤、選択的JAK阻害剤、インターロイキン標的モノクローナル抗体によって補完され、あるいは置き換えられています。

デュピルマブ（アトピー性皮膚炎治療薬）、セクキヌマブ（乾癬治療薬）、アダリムマブ（膿疱性汗腺炎治療薬）などの生物学的製剤は、外用薬が効かないような重症例の治療成績を劇的に改善しました。PDE4阻害薬やTYK2遮断薬などの低分子治療薬も、特に生物学的製剤に不耐性の患者や症状の軽い患者を対象として評価され、商品化されています。バイオシミラーの出現により、治療費が削減され、さまざまな地域での利用しやすさが向上しています。

製剤技術も進歩しており、マイクロスフェアデリバリー、フォームベースのビヒクル、ナノキャリアを強化した外用剤により、皮膚浸透性、安定性、患者のコンプライアンスが向上しています。企業は、特に脂漏性皮膚炎や薬剤耐性ニキビのような治療抵抗性疾患に対して、薬理ゲノムスクリーニングやAIによる治療マッチングを通じた個別化皮膚科学への投資を進めています。

市場力学を形成している患者セグメント、病態、チャネルは？

10代と若年成人は、特にニキビとニキビ関連瘢痕の蔓延により、処方箋皮膚科市場の大きな割合を占めています。成人層、特に30～55歳は、酒さ、肝斑、慢性蕁麻疹などの治療領域の成長に貢献しています。糖尿病や免疫不全などの合併症を抱えることの多い高齢者層は、抗真菌薬、抗ウイルス薬、抗炎症薬などの皮膚科治療薬の需要を牽引しています。

最も急成長している治療分野は、アトピー性皮膚炎、乾癬、皮膚がんなどです。環境ストレス要因、自己免疫の引き金、ライフスタイルの変化は、世界的に慢性皮膚疾患を悪化させています。都市化、汚染、長時間のスクリーン露出も、酸化ストレスや光老化に関連する皮膚疾患の一因となっています。

処方箋調剤は、デジタル薬局や専門薬局のチャネルにますますシフトしています。遠隔皮膚科は、特にサービスが行き届いていない遠隔地市場において、診断と治療開始において中心的な役割を果たしています。専門薬局、皮膚科に特化したチェーン、デジタル・プラットフォームは、自動リフィル、バーチャル診察、AIを活用した症状追跡によってコンプライアンスを向上させています。

世界の処方皮膚科治療薬市場の成長を牽引しているのは？

世界の処方皮膚科治療薬市場の成長の原動力は、慢性皮膚疾患の有病率の上昇、皮膚科研修を受けた医師の基盤の拡大、薬剤分子とデリバリーメカニズムの両方における強力な技術革新です。皮膚の健康が全身の健康やQOLの中核をなすと見なされるようになり、効果的で医学的管理の行き届いた治療に対する患者の需要が高まっています。

次世代生物学的製剤と免疫療法の商業化により、治療プロトコールが再構築され、より迅速な疾患コントロール、再発率の低下、患者の転帰の改善がもたらされています。バイオシミラーや新規の外用製剤に対する規制当局の承認は、手頃な価格と地理的アクセスの拡大をもたらしています。さらに、臨床試験や皮膚科研究開発パイプラインへの投資の拡大により、治療の多様性が増しています。

消費者のデジタル化と遠隔医療の導入は、処方箋のオンボーディング、リフィル・ロジスティックス、アドヒアランス・モニタリングの成長を支えています。アジア太平洋とラテンアメリカの市場は、皮膚科インフラの成長、可処分所得の増加、皮膚科医療に対する意識の高まりにより、力強い勢いを見せています。技術革新、デジタルヘルス、患者中心のモデルが融合する中、処方皮膚科治療薬市場は今後10年間、世界的に力強い拡大が見込まれます。

セグメント

製品タイプ（にきび・酒さ治療薬、乾癬治療薬、皮膚炎・脂漏治療薬、真菌感染症治療薬、皮膚がん治療薬、その他の製品タイプ）、流通チャネル（病院薬局、小売薬局、通販薬局）

調査対象企業の例

• AbbVie Inc.
• Almirall S.A.
• Amgen Inc.
• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Biofrontera AG
• Cassiopea SpA（Cosmo Pharma）
• Cipher Pharmaceuticals
• Dermira, Inc.（a Lilly company）
• Dr. Reddy's Laboratories
• Galderma S.A.
• Glenmark Pharmaceuticals
• Leo Pharma A/S
• Maruho Co., Ltd.
• Mayne Pharma Group Ltd
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries
• Viatris Inc.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Prescription Dermatology Therapeutics Market to Reach US$80.8 Billion by 2030

The global market for Prescription Dermatology Therapeutics estimated at US$50.4 Billion in the year 2024, is expected to reach US$80.8 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2024-2030. Acne & Rosacea Drugs, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$22.3 Billion by the end of the analysis period. Growth in the Psoriasis Drugs segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.7 Billion While China is Forecast to Grow at 13.1% CAGR

The Prescription Dermatology Therapeutics market in the U.S. is estimated at US$13.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$17.7 Billion by the year 2030 trailing a CAGR of 13.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Prescription Dermatology Therapeutics Market - Key Trends & Drivers Summarized

What Is Propelling the Shift Toward Prescription-Based Dermatology Therapies?

Prescription dermatology therapeutics represent a growing category of treatments designed to address moderate to severe skin conditions requiring medical intervention. Unlike over-the-counter skincare solutions, these therapies are used to treat chronic, inflammatory, infectious, and autoimmune dermatological conditions such as psoriasis, atopic dermatitis, rosacea, acne vulgaris, hidradenitis suppurativa, and skin cancers. With rising awareness of skin health, better access to dermatological care, and growing disease prevalence, the market has expanded significantly over the past decade.

Patients with persistent or recalcitrant conditions are increasingly being prescribed advanced topicals, oral retinoids, biologics, and systemic immunomodulators. The line between cosmetic and therapeutic dermatology is also blurring, with more patients seeking clinically validated solutions for pigmentation disorders, hair loss, and photodamage. As societal attitudes shift toward proactive skin management, even conditions once dismissed as “cosmetic nuisances” are being brought under the medical care umbrella.

Healthcare providers, including dermatologists, general physicians, and allergists, are also more inclined to prescribe specialty products amid greater disease awareness and improved diagnostic tools. Factors such as insurance coverage expansion, increased patient visits to dermatologists, and digital prescription platforms are amplifying prescription fill rates and enhancing adherence.

Which Scientific Advances and Molecule Innovations Are Reshaping Therapeutic Options?

The prescription dermatology market has seen a surge in new active pharmaceutical ingredients (APIs), targeted biologics, and delivery systems that have elevated the efficacy and safety profile of treatments. Traditional agents such as corticosteroids, retinoids, and antibiotics are now being complemented or replaced by novel immunomodulators, selective JAK inhibitors, and interleukin-targeting monoclonal antibodies that offer better disease control and fewer side effects.

Biologics such as dupilumab (for atopic dermatitis), secukinumab (for psoriasis), and adalimumab (for hidradenitis suppurativa) have dramatically improved outcomes in severe cases where topical agents fail. Small molecule therapies like PDE4 inhibitors and TYK2 blockers are also being evaluated and commercialized, especially for patients intolerant to biologics or with milder symptoms. The advent of biosimilars is reducing treatment costs and improving accessibility across different regions.

Formulation technologies have also advanced, with microsphere delivery, foam-based vehicles, and nanocarrier-enhanced topicals improving skin penetration, stability, and patient compliance. Companies are investing in personalized dermatology through pharmacogenomic screening and AI-guided therapeutic matching, especially for treatment-resistant conditions like seborrheic dermatitis or drug-resistant acne.

Which Patient Segments, Conditions, and Channels Are Shaping Market Dynamics?

Teenagers and young adults form a large proportion of the prescription dermatology market, particularly due to the widespread incidence of acne and acne-related scarring. Adult segments-especially those aged 30-55-are contributing to growth in therapeutic areas such as rosacea, melasma, and chronic urticaria. Geriatric patients, often managing comorbidities like diabetes or immune compromise, drive demand for antifungal, antiviral, and anti-inflammatory dermatological therapies.

The fastest-growing therapeutic segments include atopic dermatitis, psoriasis, and skin cancer. Environmental stressors, autoimmune triggers, and lifestyle changes are exacerbating chronic skin conditions globally. Urbanization, pollution, and prolonged screen exposure are also contributing to dermatological disorders related to oxidative stress and photoaging.

Prescription fulfillment is increasingly shifting toward digital and specialty pharmacy channels. Teledermatology is playing a central role in diagnosis and treatment initiation, particularly in underserved or remote markets. Specialty pharmacies, dermatology-focused chains, and digital platforms are improving compliance via automated refills, virtual consultations, and AI-enabled symptom tracking.

What Is Driving Growth in the Global Prescription Dermatology Therapeutics Market?

The growth in the global prescription dermatology therapeutics market is driven by the rising prevalence of chronic skin diseases, an expanding base of dermatology-trained physicians, and robust innovation in both drug molecules and delivery mechanisms. With skin health increasingly viewed as a core component of systemic health and quality of life, patient demand for effective, medically-supervised treatments is on the rise.

The commercialization of next-generation biologics and immunotherapies is reshaping treatment protocols, with faster disease control, reduced relapse rates, and improved patient outcomes. Regulatory approvals for biosimilars and novel topical formulations are enhancing affordability and expanding geographic access. In addition, growing investments in clinical trials and dermatology R&D pipelines are adding to therapeutic diversity.

Consumer digitalization and telemedicine adoption are supporting growth across prescription onboarding, refill logistics, and adherence monitoring. Markets in Asia-Pacific and Latin America are showing strong momentum due to growing dermatology infrastructure, rising disposable incomes, and awareness of dermatological health. As innovation, digital health, and patient-centric models converge, the prescription dermatology therapeutics market is positioned for strong global expansion over the next decade.

SCOPE OF STUDY:

The report analyzes the Prescription Dermatology Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs, Other Product Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AbbVie Inc.
• Almirall S.A.
• Amgen Inc.
• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Biofrontera AG
• Cassiopea SpA (Cosmo Pharma)
• Cipher Pharmaceuticals
• Dermira, Inc. (a Lilly company)
• Dr. Reddy's Laboratories
• Galderma S.A.
• Glenmark Pharmaceuticals
• Leo Pharma A/S
• Maruho Co., Ltd.
• Mayne Pharma Group Ltd
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries
• Viatris Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Prescription Dermatology Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rise in Skin Condition Prevalence Throws the Spotlight On Prescription Dermatology Innovations
  • Growth in Chronic Dermatological Disorders Drives Demand for Targeted Prescription Therapies
  • Advancements in Biologics and Small Molecule Drugs Strengthen Market for Specialty Skin Treatments
  • Expansion of Teledermatology Platforms Propels Prescription Accessibility and Market Penetration
  • Increasing Diagnosis of Psoriasis and Atopic Dermatitis Expands Addressable Therapeutic Opportunity
  • Regulatory Approvals of Novel Monoclonal Antibodies Drive Growth in Autoimmune Dermatology Segments
  • Rise in Personalized Medicine and Companion Diagnostics Spurs Use of Genotype-Specific Skin Treatments
  • Investment in AI-Based Skin Condition Screening Enhances Clinical Precision and Prescribing Confidence
  • Integration of Digital Prescriptions and Online Consultations Accelerates Treatment Initiation
  • Shift Toward Evidence-Based Dermatologic Guidelines Strengthens Business Case for Advanced Therapeutics
  • Rising Incidence of Skin Cancer and Actinic Keratosis Drives Demand for Prescription Oncology Dermatology Drugs
  • Growth in Aesthetic Dermatology Clinics Expands Use of Combination Prescription Therapies
  • Expansion of Patient Assistance Programs Improves Access to High-Cost Dermatological Medications
  • Increased Emphasis on Long-Term Disease Control and Remission Supports Adherence to Prescription Protocols
  • Launch of Novel Topicals With Advanced Delivery Mechanisms Drives Innovation in Non-Invasive Formulations
  • Regulatory Support for Fast-Track Designations Encourages Pipeline Acceleration in Dermatology Drugs
  • Rising Demand for Hormonal and Anti-Androgen Skin Therapies Boosts Female-Focused Dermatologic Prescriptions
  • Growth in Pediatric Dermatology Segments Spurs Market Entry of Age-Specific Prescription Formulations
  • Surge in Awareness Campaigns Around Eczema and Acne Fuels Demand for Physician-Driven Treatments
  • Collaborations With Dermatology Societies Strengthen Clinical Trial Networks and Therapeutic Development
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Prescription Dermatology Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Prescription Dermatology Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Prescription Dermatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Acne & Rosacea Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Acne & Rosacea Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Acne & Rosacea Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Psoriasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Psoriasis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Psoriasis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Dermatitis & Seborrhea Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Dermatitis & Seborrhea Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Dermatitis & Seborrhea Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Fungal Infection Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Fungal Infection Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Fungal Infection Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Skin Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Skin Cancer Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Skin Cancer Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Mail Order Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Mail Order Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Mail Order Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• JAPAN
  • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• CHINA
  • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 50: China Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: China 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 53: China Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: China 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• EUROPE
  • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Prescription Dermatology Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Prescription Dermatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Europe 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• FRANCE
  • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 65: France Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: France 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 68: France Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: France 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• GERMANY
  • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Germany 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Germany 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Italy 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Italy 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 83: UK Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: UK 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 86: UK Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: UK 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Spain 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Spain 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Russia 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Russia 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Rest of Europe 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Rest of Europe 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Prescription Dermatology Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Prescription Dermatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Asia-Pacific 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Australia 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Australia 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• INDIA
  • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 122: India Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: India 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 125: India Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: India 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: South Korea 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: South Korea 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Prescription Dermatology Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Prescription Dermatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Latin America 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Argentina 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Argentina 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Brazil 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Brazil 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Mexico 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Mexico 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Rest of Latin America 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Rest of Latin America 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Prescription Dermatology Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Prescription Dermatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Middle East 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Iran 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Iran 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Israel 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Israel 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Saudi Arabia 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Saudi Arabia 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: UAE 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: UAE 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Rest of Middle East 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Rest of Middle East 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030
• AFRICA
  • Prescription Dermatology Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Prescription Dermatology Therapeutics by Product Type - Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Africa 16-Year Perspective for Prescription Dermatology Therapeutics by Product Type - Percentage Breakdown of Value Sales for Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs and Other Product Types for the Years 2014, 2025 & 2030
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Prescription Dermatology Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Africa 16-Year Perspective for Prescription Dermatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Mail Order Pharmacies for the Years 2014, 2025 & 2030

IV. COMPETITION